Source and scope
This summary is bounded to the recommendations, population and decisions covered by Guideline No. 449: Diagnosis and Impact of Endometriosis – A Canadian Guideline. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC 449
Source-attributed clinical priorities
- Suspect endometriosis from cyclic or persistent pelvic pain, dysmenorrhea, dyspareunia, bowel or bladder symptoms and infertility impact.
- A clinical or imaging diagnosis can support care; laparoscopy is not required as the first diagnostic step for every patient.
- Discuss analgesic, hormonal, fertility and surgical options and refer complex, deep or refractory disease to experienced care.
- A normal ultrasound does not exclude superficial endometriosis when the clinical pattern is convincing.
sources for this section:SOGC 449
Practical assessment and management workflow
1
Map cyclic and noncyclic pelvic pain, dyspareunia, bowel or bladder symptoms, bleeding, fertility and previous treatment.
2
Examine with consent and use pelvic ultrasound to identify endometrioma or deep disease when indicated.
3
Offer empiric analgesic and hormonal treatment when suitable while arranging specialist evaluation for complex disease.
4
Review pain, function, adverse effects and fertility goals and avoid repeated ineffective short trials.
sources for this section:SOGC 449
Safety, red flags and urgent escalation
- Urgently assess acute severe pain, pregnancy, hemodynamic instability or possible torsion or rupture.
- Refer ureteric, bowel or deep infiltrating disease to a team with appropriate surgical expertise.
- Do not promise that hysterectomy alone will cure all endometriosis-related pain.
sources for this section:SOGC 449
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC 449
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC 449
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Society of Obstetricians and Gynaecologists of CanadaGuideline No. 449: Diagnosis and Impact of Endometriosis – A Canadian Guidelineaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.